{"nctId":"NCT00809328","briefTitle":"The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)","startDateStruct":{"date":"2009-02"},"conditions":["Community Acquired Pneumonia (CAP)"],"count":102,"armGroups":[{"label":"Azithromycin","type":"EXPERIMENTAL","interventionNames":["Drug: Azithromycin"]}],"interventions":[{"name":"Azithromycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 16 years of age or older patients with CAP.\n* Patients who were diagnosed as moderate in severity.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or ketolides.\n* Hepatic dysfunction (AST, ALT, total bilirubin \\> 3 times institutional normal).\n* Severe renal dysfunction (creatinine clearance \\< 30 ml/min).\n* Patients who have a history of severe heart diseases (4th -degree of NYHA). Patients who have a congenital or sporadic long QT syndrome, or who are received the drugs with reported QT prolongation.\n* Severe underlying disease.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Response Rate (Clinical Response, Data Review Committee Assessment)","description":"Response rate was calculated from the following formula, \"the number of participants assessed as effective\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate (Clinical Response, Investigator Assessment)","description":"Response rate was calculated from the following formula, \"the number of participants assessed as effective\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Tendency Toward Clinical Improvement (Investigator Assessment)","description":"The number of participants who showed tendency toward clinical improvement based on the assessment of temperature, white blood cell count, C-reactive protein, clinical symptoms on Day 3, and was determined to continue the treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Eradication Rate (Bacteriological Response, Data Review Committee Assessment)","description":"Eradication Rate was calculated from the following formula, \"the number of participants assessed as eradication , presumed eradication or microbial substitution\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Eradication Rate (Bacteriological Response, Investigator Assessment)","description":"Eradication Rate was calculated from the following formula, \"the number of participants assessed as eradication , presumed eradication or microbial substitution\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":102},"commonTop":["Diarrhoea","Constipation","Headache","Injection site pain","Insomnia"]}}}